The effect of continuous release of recombinant human epidermal growth factor (rh-EGF) in chitosan film on full thickness excisional porcine wounds.
The purpose of this article is to evaluate the effect of continuously released recombinant human epidermal growth factor (rh-EGF) in chitosan film in full thickness porcine wounds. A total of 10 domestic pigs (Yorkshire species) weighing 18 to 22 kg between the ages of 50 to 60 days were used. The wounds were divided into 3 groups and treated selectively with rh-EGF in chitosan film (EGF 20 ug/wound/d), chitosan film without rh-EGF, or remained as the control group. One hundred percent healing time was observed, and hematoxylin and eosin and Anti Ki-67 antibody immunohistochemical staining were performed. The 100% healing time and Anti Ki-67 antibody immunohistochemical staining showed statistical significance of the rh-EGF chitosan film-treated group against the control group (P < 0.05). But it did not reveal any statistical significance over the chitosan film-treated group. In this preliminary study, although continuous release of rh-EGF in chitosan film accelerates epithelialization, the benefit of the combination of rh-EGF in chitosan cannot be determined over the use of chitosan alone. Further analysis using complex wound models such as diabetes or infection, which may have different pathology in healing, will be needed to evaluate the potential benefit/synergistic effectiveness.
Hong
Joon Pio
JP
Department of Plastic and Reconstructive Surgery, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea. joonphong@amc.seoul.kr
Kim
Yeun Wha
YW
Lee
Sang Kil
SK
Kim
Sun Hee
SH
Min
Kyung Hyun
KH
D000818:Animals; D047070:Bandages, Hydrocolloid; D048271:Chitosan / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004815:Epidermal Growth Factor / Q000008:administration & dosage*; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage; D012867:Skin / Q000293:injuries* / Q000473:pathology; D013552:Swine; D014945:Wound Healing / Q000187:drug effects*; D014950:Wounds, Penetrating / Q000473:pathology / Q000628:therapy*
D003692:Delayed-Action Preparations; D004337:Drug Carriers; D011994:Recombinant Proteins; D004815:Epidermal Growth Factor; D048271:Chitosan